Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Q3 2025 value amounting to $81262.0.

  • Cumberland Pharmaceuticals' Share-based Compensation rose 640.43% to $81262.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $310972.0, marking a year-over-year decrease of 311.7%. This contributed to the annual value of $301895.0 for FY2024, which is 1729.81% down from last year.
  • As of Q3 2025, Cumberland Pharmaceuticals' Share-based Compensation stood at $81262.0, which was up 640.43% from $80686.0 recorded in Q2 2025.
  • Cumberland Pharmaceuticals' 5-year Share-based Compensation high stood at $224786.0 for Q4 2021, and its period low was -$27753.0 during Q2 2022.
  • Its 5-year average for Share-based Compensation is $110129.7, with a median of $90156.0 in 2023.
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Share-based Compensation plummeted by 11445.82% in 2022, and later surged by 45267.54% in 2023.
  • Quarter analysis of 5 years shows Cumberland Pharmaceuticals' Share-based Compensation stood at $224786.0 in 2021, then tumbled by 43.54% to $126905.0 in 2022, then dropped by 26.01% to $93894.0 in 2023, then fell by 20.32% to $74812.0 in 2024, then grew by 8.62% to $81262.0 in 2025.
  • Its Share-based Compensation stands at $81262.0 for Q3 2025, versus $80686.0 for Q2 2025 and $74212.0 for Q1 2025.